

*Savas Yayli**Murat Cakir*

Dear colleagues,

It is a big pleasure to present the first issue of this year, 2023 is the 6th year of Mucosa's publishing life.

In this issue, we have five scientific articles for you. Hande Ermis Akkus reviewed a cutting-edge technologic treatment modality, chimeric autoantibody receptor T cell therapy, which is a promising therapy beyond last approved pemphigus treatment, rituximab. Salici et al. reported a generalized subcorneal pustular dermatosis involving lips which was successfully treated with cyclosporine. The classic pustular lesions on the lips are very demonstrative. In the second case report, Ozcanli et al. also presented a demonstrative giant wart on the tongue, observed incidentally during physical examination of a patient who want to be a kidney donor. Cowan et al. reported a chronic, refractory cheilitis without any obvious allergen or clear trigger which has been shown a significant response to tildrakizumab, an IL-23 inhibitor. Lastly, Salici et al. reported a patient with widespread oral ulcerations which is attributed to methamphetamine use after the elimination of all possible causes including infections, inflammatory conditions and malignancies.

We cordially thank our readers, authors, reviewers, and our publisher for their meritorious contributions. We await your valuable contributions to our forthcoming issues.

Warm regards,

*Murat Cakir*

*Savas Yayli*

Co-editors